Soleno Therapeutics Inc has announced that the US Food and Drug Administration granted Breakthrough Therapy Designation to diazoxide choline for the treatment of adults and children aged

AriBio Co Ltd has received approval from the European Medicines Agency for POLARISAD a phase clinical trial targeting early Alzheimers disease This approval aligns with similar authorizations

Beijing Avistone Biotechnology Co Ltd has gained approval from the Chinese National Medical Products Administration to extend the application of vebreltinib for treating adult patients

Hyundai Bioscience made headlines on April th with its breakthrough announcement regarding the development of an oral anticancer drug targeting patients with intractable cancers

Apollomics Inc has announced a significant development regarding vebreltinib in China The National Medical Products Administration has granted approval to Avistone Biotechnology Co Ltd

Amneal Pharmaceuticals Inc has unveiled its Over the Counter Naloxone Hydrochloride Nasal Spray USP mg after securing Abbreviated New Drug Application approval from the US Food and Drug Administration

BioTechne Corporation a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities is pleased to announce a significant milestone

Sino Biological Inc a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext specializing in biological research reagents and related technical contract research services

ENA Respiratory a clinicalstage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in atrisk populations announces

Ractigen Therapeutics a leader in the development of small activating RNA therapeutics announced today that the US Food and Drug Administration has approved the companys Investigational New Drug

HUTCHMED today announces that its partner Takeda received notification that the Committee for Medicinal Products for Human Use of the European Medicines Agency

Our customers depend on the high performance and reliability of the plates used in their highthroughput processes However increased throughput results in a higher carbon footprint